PAR SIGNALING AND PROTECTIVE PATHWAYS IN INFLAMMATION AND SEPSIS

炎症和脓毒症中的 PAR 信号传导和保护途径

基本信息

  • 批准号:
    7929579
  • 负责人:
  • 金额:
    $ 67.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-15 至 2011-08-31
  • 项目状态:
    已结题

项目摘要

The intrinsic signaling aspects of the coagulation cascade have emerged as major contributors and regulators of systemic inflammation and sepsis. Our experiments uncovered an unexpected thrombin-protease activated receptor (PAR) 1 signaling pathway on dendritic cells (DCs) that is responsible for exacerbated systemic inflammatory response syndromes leading to sepsis lethality. Thrombin-activated PAR1 uniquely couples to sphingosine 1 phosphate (S1P) receptor 3 (S1P3) to promote DC-dependent inflammation and to induce endothelial dysfunction and vascular leakage. Paradoxically, PAR1 signaling by endogenous or therapeutically administered activated protein C (aPC) is sepsis protective. Our data indicate that therapeutic action of aPC targets both DC-dependent inflammation and vascular leakage, excluding that the “PAR1 paradox” can simply be reduced to cell type specific signaling effects. We propose to test the overall hypothesis that coupling of PAR1 to S1P receptor subtypes and regulatory co-receptors are the key determinants for the observed protease signaling specificity of PAR activation in vivo. The experiments in the upcoming two years will advance these concepts by focusing on the role of PAR1 signaling in DCs and endothelial cells. Aim 1 is to define the specific cell populations that are the target for thrombin and aPC signaling to regulate innate immune function in severe sepsis. These experiments advance our understanding of the innate immune cells that are controlled by the intrinsic signaling of the coagulation cascade and lay the foundation for testing new concepts of pharmacological modulation of the pro-inflammatory PAR1-S1P3 signaling pathway of DCs. In Aim 2, we use genetic and pharmacological perturbations of the intravascular coagulant balance to further characterize the dual role of PAR1 as a barrier disruptive and barrier protective receptor in sepsis. These experiments expand our knowledge of how co-receptors of PAR1 signaling contribute to the regulation of vascular barrier function and set the stage for further testing of new therapeutic strategies that improve vascular dysfunction in inflammatory disorders and sepsis. 3.
凝血级联的内在信号方面已成为全身性炎症和败血症的主要贡献者和调节剂。我们的实验揭示了树突状细胞(dc)上一个意想不到的凝血酶蛋白酶激活受体(PAR) 1信号通路,该信号通路是导致败血症致死的系统性炎症反应综合征加重的原因。凝血酶激活的PAR1独特地与S1P受体3 (S1P3)偶联,促进dc依赖性炎症,诱导内皮功能障碍和血管渗漏。矛盾的是,内源性或治疗性给予活化蛋白C (aPC)的PAR1信号具有脓毒症保护作用。我们的数据表明,aPC的治疗作用既针对dc依赖性炎症,也针对血管渗漏,排除了“PAR1悖论”可以简单地归结为细胞类型特异性信号传导效应。我们提出验证PAR1与S1P受体亚型和调节共受体的偶联是在体内观察到的PAR激活的蛋白酶信号特异性的关键决定因素的总体假设。未来两年的实验将通过关注PAR1信号在dc和内皮细胞中的作用来推进这些概念。目的1是确定凝血酶和aPC信号在严重脓毒症中调节先天免疫功能的特定靶细胞群。这些实验促进了我们对固有免疫细胞受凝血级联内在信号控制的认识,并为测试DCs促炎PAR1-S1P3信号通路的药理调节新概念奠定了基础。在Aim 2中,我们使用血管内凝血剂平衡的遗传和药理学扰动来进一步表征PAR1在败血症中作为屏障破坏和屏障保护受体的双重作用。这些实验扩大了我们对PAR1信号的共受体如何促进血管屏障功能调节的认识,并为进一步测试改善炎症性疾病和败血症血管功能障碍的新治疗策略奠定了基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WOLFRAM RUF其他文献

WOLFRAM RUF的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WOLFRAM RUF', 18)}}的其他基金

PAR SIGNALING AND PROTECTIVE PATHWAYS IN INFLAMMATION AND SEPSIS
炎症和脓毒症中的 PAR 信号传导和保护途径
  • 批准号:
    7743980
  • 财政年份:
    2009
  • 资助金额:
    $ 67.07万
  • 项目类别:
Toward a Repertoire of Genetic Models for Coagulation Signaling in Chronic Inflam
建立慢性炎症凝血信号传导的遗传模型
  • 批准号:
    7933941
  • 财政年份:
    2009
  • 资助金额:
    $ 67.07万
  • 项目类别:
Proteases in Hemostasis and Vascular Biology
止血和血管生物学中的蛋白酶
  • 批准号:
    7673045
  • 财政年份:
    2009
  • 资助金额:
    $ 67.07万
  • 项目类别:
Toward a Repertoire of Genetic Models for Coagulation Signaling in Chronic Inflam
建立慢性炎症凝血信号传导的遗传模型
  • 批准号:
    7826468
  • 财政年份:
    2009
  • 资助金额:
    $ 67.07万
  • 项目类别:
Regulation of Endothelial Cell Procoagulant Properties
内皮细胞促凝血特性的调节
  • 批准号:
    7029344
  • 财政年份:
    2005
  • 资助金额:
    $ 67.07万
  • 项目类别:
NEW GENETIC MODELS FOR TISSUE FACTOR SIGNALING
组织因子信号转导的新遗传模型
  • 批准号:
    6815174
  • 财政年份:
    2004
  • 资助金额:
    $ 67.07万
  • 项目类别:
TARGETING SIGNALING OF THE TISSUE FACTOR PATHWAY
组织因子通路的靶向信号传导
  • 批准号:
    7113188
  • 财政年份:
    2004
  • 资助金额:
    $ 67.07万
  • 项目类别:
TF Signaling in Systemic Inflammation
系统性炎症中的 TF 信号转导
  • 批准号:
    7911750
  • 财政年份:
    2004
  • 资助金额:
    $ 67.07万
  • 项目类别:
TF Signaling in Systemic Inflammation
系统性炎症中的 TF 信号转导
  • 批准号:
    7524943
  • 财政年份:
    2004
  • 资助金额:
    $ 67.07万
  • 项目类别:
NEW GENETIC MODELS FOR TISSUE FACTOR SIGNALING
组织因子信号转导的新遗传模型
  • 批准号:
    6908126
  • 财政年份:
    2004
  • 资助金额:
    $ 67.07万
  • 项目类别:

相似海外基金

EPIphANy (Evaluation of Pharmacological Interactions with Anticoagulants in caNcer patients) program - prostate cancer cohort
EPIPHANy(癌症患者抗凝药理相互作用的评估)计划 - 前列腺癌队列
  • 批准号:
    479295
  • 财政年份:
    2023
  • 资助金额:
    $ 67.07万
  • 项目类别:
    Operating Grants
Inhibitors of Human Factor XIIIa as New Anticoagulants
人类因子 XIIIa 抑制剂作为新型抗凝剂
  • 批准号:
    10629057
  • 财政年份:
    2023
  • 资助金额:
    $ 67.07万
  • 项目类别:
Establishment of comprehensive monitoring of direct oral anticoagulants (DOACs) for clinical application
建立临床应用直接口服抗凝剂(DOAC)综合监测体系
  • 批准号:
    23K06906
  • 财政年份:
    2023
  • 资助金额:
    $ 67.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Interactions of Enzyme-Inducing Antiepileptic Drugs with Direct-Acting Oral Anticoagulants: Risk of Thromboembolic Events
酶诱导抗癫痫药物与直接作用口服抗凝剂的相互作用:血栓栓塞事件的风险
  • 批准号:
    10605482
  • 财政年份:
    2023
  • 资助金额:
    $ 67.07万
  • 项目类别:
The Comparative Effectiveness and Safety of Oral Anticoagulants in Patients with Cirrhosis and Atrial Fibrillation
口服抗凝药对肝硬化合并心房颤动患者的有效性和安全性比较
  • 批准号:
    10559071
  • 财政年份:
    2023
  • 资助金额:
    $ 67.07万
  • 项目类别:
Search for indicators of blood levels of directly inhibitory oral anticoagulants in coagulation tests using artificial intelligence
使用人工智能在凝血测试中搜索直接抑制性口服抗凝剂的血液水平指标
  • 批准号:
    22K07388
  • 财政年份:
    2022
  • 资助金额:
    $ 67.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Bleeding on Direct Oral Anticoagulants: Identification of Genetic Risk Factors and a Polygenic Predictive Score in Patients with Atrial Fibrillation
直接口服抗凝剂导致的出血:房颤患者遗传风险因素的鉴定和多基因预测评分
  • 批准号:
    10536789
  • 财政年份:
    2022
  • 资助金额:
    $ 67.07万
  • 项目类别:
Study on proper use of oral anticoagulants combined with 5-fluorouracil
口服抗凝药联合5-氟尿嘧啶正确使用研究
  • 批准号:
    22K06743
  • 财政年份:
    2022
  • 资助金额:
    $ 67.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Benchmarking a point-of-care test kit for detection of direct-oral anticoagulants
用于检测直接口服抗凝剂的即时检测试剂盒的基准测试
  • 批准号:
    461790
  • 财政年份:
    2022
  • 资助金额:
    $ 67.07万
  • 项目类别:
    Operating Grants
Direct oral anticoagulants and the risk of colorectal and pancreatic cancers: a population-based cohort study.
直接口服抗凝剂与结直肠癌和胰腺癌的风险:一项基于人群的队列研究。
  • 批准号:
    474475
  • 财政年份:
    2022
  • 资助金额:
    $ 67.07万
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了